Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Literature DB >> 23451330

The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Shan Muhammad¹, Zheng Jiang, Zheng Liu, Kavanjit Kaur, Xishan Wang.

Abstract

Entities: Chemical Disease Gene

Year: 2013 PMID： 23451330 PMCID： PMC3562627 DOI： 10.3978/j.issn.2078-6891.2012.044

Source DB: PubMed Journal: J Gastrointest Oncol ISSN： 2078-6891

× No keyword cloud information.

78 in total

1. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.

Authors: Hirotoshi Kikuchi; Maria S Pino; Min Zeng; Senji Shirasawa; Daniel C Chung
Journal: Cancer Res Date: 2009-10-20 Impact factor: 12.701

Review 2. Hypoxia-responsive transcription factors.

Authors: Eoin P Cummins; Cormac T Taylor
Journal: Pflugers Arch Date: 2005-07-09 Impact factor: 3.657

3. BRAF mutation predicts sensitivity to MEK inhibition.

Authors: David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal: Nature Date: 2005-11-06 Impact factor: 49.962

4. Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients.

Authors: Carla G Rasuck; Sinara M O Leite; Flavia Komatsuzaki; Alessandro C S Ferreira; Vanessa C Oliveira; Karina B Gomes
Journal: Mol Biol Rep Date: 2011-06-17 Impact factor: 2.316

5. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.

Authors: Klaus P Hoeflich; Daniel C Gray; Michael T Eby; Janet Y Tien; Leo Wong; Janeko Bower; Alvin Gogineni; Jiping Zha; Mary J Cole; Howard M Stern; Lesley J Murray; David P Davis; Somasekar Seshagiri
Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701

6. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

Authors: Ludovic Barault; Nicolas Veyrie; Valerie Jooste; Delphine Lecorre; Caroline Chapusot; Jean-Marc Ferraz; Astrid Lièvre; Marion Cortet; Anne-Marie Bouvier; Patrick Rat; Patrick Roignot; Jean Faivre; Pierre Laurent-Puig; Francoise Piard
Journal: Int J Cancer Date: 2008-05-15 Impact factor: 7.396

7. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544

The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

1. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.

Review 2. Hypoxia-responsive transcription factors.

3. BRAF mutation predicts sensitivity to MEK inhibition.

4. Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients.

5. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.

6. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

7. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

8. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

Review 9. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

10. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Review 1. Therapeutic modulators of STAT signalling for human diseases.

Review 2. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Review 3. The State of the Art in Colorectal Cancer Molecular Biomarker Testing.